GHRS
GH Research PLC
$20.35
+1.14%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Reddit Sentiment67° Warm
SEC Reports6
Press Releases2
Recent Activity
May 14, 2026
SEC
GH Research PLC filed a 424B5 prospectus supplement to register an at-the-market (ATM) equity offering of up to $200 mil
424B5 — Impact 6/10
May 14, 2026
SEC
GH Research PLC reported Q1 2026 financial results showing a net loss of $19.0 million ($0.31 per share), compared to a
6-K — Impact 5/10
May 14, 2026
SEC
GH Research reported Q1 2026 EPS of -$0.31, wider than the -$0.26 consensus estimate (a ~19% miss on a GAAP basis), and
PRESS-RELEASE — Impact 6/10
May 14, 2026
earnings
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="justify">DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clin
Mar 25, 2026
Press
GH Research PLC announced the publication of Phase 2b trial results for its lead candidate GH001 in treatment-resistant
Impact 8/10
Mar 5, 2026
Press
GH Research reported financial results for 2025, highlighted by a strong Phase 2b trial for GH001 in treatment-resistant
Impact 8/10
Price Targets
$39.50
+94.1% upside
Strong Buy
Current $20.35
Low $32.00
Median $37.00
High $65.00
8 analysts
$32.00
$65.00
Analyst Ratings
4Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 15, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| May 15, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 6, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 6, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.32 ▼ -10.1% | $-0.37 — $-0.27 | -112% YoY | 8 |
| Next Q | $-0.36 ▼ -6.2% | $-0.46 — $-0.27 | -57% YoY | 8 |
| Current FY | $-1.40 ▼ -5.9% | $-1.56 — $-1.18 | -78% YoY | 8 |
| Next FY | $-2.00 ▼ -8.9% | $-2.80 — $-1.54 | -43% YoY | 8 |
Latest Reports
BEARISH
424B5
6/10
GH Research PLC filed a 424B5 prospectus supplement to register an at-the-market (ATM) equity offering of up to $200 mil
May 14, 2026
NEUTRAL
6-K
5/10
GH Research PLC reported Q1 2026 financial results showing a net loss of $19.0 million ($0.31 per share), compared to a
May 14, 2026
BULLISH
Press
8/10
GH Research PLC announced the publication of Phase 2b trial results for its lead candidate GH001 in treatment-resistant
Mar 25, 2026
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 2 neutral. Avg impact: 5.2/10.
BEARISH
424B5
6/10
GH Research PLC filed a 424B5 prospectus supplement to register an at-the-market (ATM) equity offeri
May 14, 2026
NEUTRAL
6-K
5/10
GH Research PLC reported Q1 2026 financial results showing a net loss of $19.0 million ($0.31 per sh
May 14, 2026
MIXED
PRESS-RELEASE
6/10
GH Research reported Q1 2026 EPS of -$0.31, wider than the -$0.26 consensus estimate (a ~19% miss on
May 14, 2026
BEARISH
6-K
6/10
GH Research filed its 2025 annual report (Form 20-F) via a 6-K, revealing a net loss of $48.3 millio
May 13, 2026
BEARISH
424B5
6/10
GH Research PLC priced a follow-on offering of 6,527,779 ordinary shares at $18.00 per share, a 9.3%
Apr 29, 2026
NEUTRAL
3
2/10
Florian Schonharting, a reporting person at GH Research PLC, filed a Form 3 to report initial benefi
Apr 1, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 15 analysts: 4 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.50 mean target
+94.1% upside
Strong Buy (3.00)
$32.00 Low
$65.00 High
| Metric | Value |
|---|---|
| Current Price | $20.35 |
| Target Low | $32.00 |
| Target Mean | $39.50 |
| Target Median | $37.00 |
| Target High | $65.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.32 | $-0.37 | $-0.27 | -111.7% | -10.1% | 1↑ 5↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.36 | $-0.46 | $-0.27 | -57.1% | -6.2% | 1↑ 5↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-1.40 | $-1.56 | $-1.18 | -77.5% | -5.9% | 1↑ 6↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-2.00 | $-2.80 | $-1.54 | -42.5% | -8.9% | 1↑ 6↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.318 | |
| 7d ago | $-0.288 | -0.029 |
| 30d ago | $-0.288 | -0.029 |
| 60d ago | $-0.288 | -0.029 |
| 90d ago | $-0.313 | -0.005 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| May 15, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 6, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 14, 2026
earnings
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="justify">DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to
May 7, 2026
earnings_calendar
GHRS Q1 2026 Earnings Scheduled — 2026-05-07
Mar 25, 2026
fda
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
<p align="justify">DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated t
Mar 24, 2026
short_interest
FTD: GHRS — 52,702 shares ($0.7M) failed to deliver
Settlement: 20260324, Price: $13.21, FTD Value: $696,193.42, GH RESH PLC SHS (IRL)
Mar 6, 2026
short_interest
FTD: GHRS — 222,694 shares ($3.4M) failed to deliver
Settlement: 20260306, Price: $15.17, FTD Value: $3,378,267.98, GH RESH PLC SHS (IRL)
Mar 5, 2026
earnings
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
<p align="justify">DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company de
Feb 26, 2026
earnings_calendar
GHRS Q4 2025 Earnings After Market Close — 2026-02-26
Feb 17, 2026
short_interest
FTD: GHRS — 42,135 shares ($0.6M) failed to deliver
Settlement: 20260217, Price: $14.70, FTD Value: $619,384.5, GH RESH PLC SHS (IRL)